Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 13, 2013 - Issue 2
Submit an article Journal homepage
413
Views
16
CrossRef citations to date
0
Altmetric
Research Report

Cost–effectiveness analysis comparing degarelix with leuprolide in hormonal therapy for patients with locally advanced prostate cancer

Hind T Hatoum Hind T Hatoum & Company, 155 N Harbor Drive, 1912, Chicago, IL 60601, USA. [email protected]
,
E David Crawford University of Colorado, Denver, Mail Stop F 710, PO Box 6510, Aurora, CO 80045, USA
,
Sandy Kildegaard Nielsen Ferring International Center SA, Chemin de la Vergognausaz 50, CH-1162 St. Prex, Switzerland
,
Swu-Jane Lin Department of Pharmacy Administration, College of Pharmacy, University of Illinois at Chicago, 833 South Wood St., Chicago, IL 60612, USA
&
Dennis C Marshall Ferring Pharmaceuticals, Inc., 4 Gatehall Drive, Parsippany, NJ 07054, USA
Pages 261-270 | Published online: 09 Jan 2014

Citations (16)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Mohamad Moussa, Athanasios Papatsoris, Despoina Sryropoulou, Mohamed Abou Chakra, Athanasios Dellis & Lazaros Tzelves. (2021) A pharmacoeconomic evaluation of pharmaceutical treatment options for prostate cancer. Expert Opinion on Pharmacotherapy 22:13, pages 1685-1728.
Read now
David D. Kim, Colby L. Wilkinson, Elle F. Pope, James D. Chambers, Joshua T. Cohen & Peter J. Neumann. (2017) The influence of time horizon on results of cost-effectiveness analyses. Expert Review of Pharmacoeconomics & Outcomes Research 17:6, pages 615-623.
Read now
Athanasios Dellis & Athanasios Papatsoris. (2017) Therapeutic outcomes of the LHRH antagonists. Expert Review of Pharmacoeconomics & Outcomes Research 17:5, pages 481-488.
Read now
Timothy N. Clinton, Solomon L. Woldu & Ganesh V. Raj. (2017) Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer. Expert Opinion on Pharmacotherapy 18:8, pages 825-832.
Read now
Dawn Lee, Joshua Porter, Daniel Gladwell, Nic Brereton & Sandy K. Nielsen. (2014) A cost–utility analysis of degarelix in the treatment of advanced hormone-dependent prostate cancer in the United Kingdom. Journal of Medical Economics 17:4, pages 233-247.
Read now

Articles from other publishers (11)

Olajide A. Adekunle, Enrique Seoane-Vazquez & Lawrence M. Brown. (2023) Cost-effectiveness analysis of androgen deprivation therapy with relugolix for the treatment of advanced prostate cancer. Journal of the American Pharmacists Association 63:3, pages 817-824.e3.
Crossref
Jianzhou Yan, Caiyun Li, Xuefang Zhang, Luyan Cheng, Ruilin Ding & Lingli Zhang. (2022) Degarelix vs. leuprorelin for the treatment of prostate cancer in China: A cost-utility analysis. Frontiers in Public Health 10.
Crossref
Fred Saad & Neal D. Shore. (2021) Relugolix: a novel androgen deprivation therapy for management of patients with advanced prostate cancer. Therapeutic Advances in Medical Oncology 13, pages 175883592199858.
Crossref
Joseph H Lipton, Mahdi Zargar, Ellen Warner, Ellen E Greenblatt, Esther Lee, Kelvin K W Chan & William W L Wong. (2020) Cost effectiveness of in vitro fertilisation and preimplantation genetic testing to prevent transmission of BRCA1/2 mutations. Human Reproduction 35:2, pages 434-445.
Crossref
Sung-Hee Jeon & R. Vincent Pohl. (2019) Medical innovation, education, and labor market outcomes of cancer patients. Journal of Health Economics 68, pages 102228.
Crossref
Alyssa K. Greiman & Thomas E. Keane. (2017) Approach to Androgen Deprivation in the Prostate Cancer Patient with Pre-existing Cardiovascular Disease. Current Urology Reports 18:6.
Crossref
F. Kunath, H. Borgmann, A. Blu mle, B. Keck, B. Wullich, C. Schmucker, D. Sikic, C. Roelle, S. Schmidt, A. Wahba & J. J. Meerpohl. (2015) Gonadotropin-releasing hormone antagonists versus standard androgen suppression therapy for advanced prostate cancer A systematic review with meta-analysis. BMJ Open 5:11, pages e008217-e008217.
Crossref
W Niżański, X Levy, M Ochota & J Pasikowska. (2014) Pharmacological Treatment for Common Prostatic Conditions in Dogs - Benign Prostatic Hyperplasia and Prostatitis: an Update. Reproduction in Domestic Animals 49, pages 8-15.
Crossref
E. David Crawford, Neal D. Shore, Judd W. Moul, Bertrand Tombal, Fritz H. Schröder, Kurt Miller, Laurent Boccon-Gibod, Anders Malmberg, Tine Kold Olesen, Bo-Eric Persson & Laurence Klotz. (2014) Long-term Tolerability and Efficacy of Degarelix: 5-Year Results From a Phase III Extension Trial With a 1-Arm Crossover From Leuprolide to Degarelix. Urology 83:5, pages 1122-1128.
Crossref
Gábor Mezo. 2013. Amino Acids, Peptides and Proteins. Amino Acids, Peptides and Proteins 203 252 .
Sung-Hee Jeon & R. Vincent Pohl. (2019) Medical Innovation, Education, and Labor Market Outcomes of Cancer Patients. SSRN Electronic Journal.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.